Prosecution Insights
Last updated: April 19, 2026

Examiner: HUMPHRIES, NICHOLAS ADAM

Tech Center 1600 • Art Units: 1631

This examiner grants 38% of resolved cases

Performance Statistics

37.5%
Allow Rate
-22.5% vs TC avg
71
Total Applications
+82.2%
Interview Lift
1385
Avg Prosecution Days
Based on 24 resolved cases, 2023–2026

Rejection Statute Breakdown

4.3%
§101 Eligibility
18.0%
§102 Novelty
36.0%
§103 Obviousness
28.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18034042 VECTORIZED TNF-ALPHA ANTAGONISTS FOR OCULAR INDICATIONS Non-Final OA REGENXBIO INC.
18246087 NOVEL ENHANCED BASE EDITING OR REVISING FUSION PROTEIN AND USE THEREOF Non-Final OA KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
18042726 VIRAL VECTORS ENCODING GLP-1 RECEPTOR AGONIST FUSIONS AND USES THEREOF IN TREATING METABOLIC DISEASES Non-Final OA The Trustees of the University of Pennsylvania
17907229 INDUCIBLE PROMOTER FOR VIRAL VECTOR PRODUCTION Non-Final OA ASKBIO INC.
18262799 PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE Non-Final OA The Trustees of Indiana University
18266951 CULTURE MATERIAL AND USE THEREOF Non-Final OA MITSUI CHEMICALS, INC.
18808041 MITOCHONDRIA ISOLATION FROM CELLS IN SUSPENSION Non-Final OA CELLERGY THERAPEUTICS LTD
18350986 CELLS AND METHOD OF CELL CULTURE Non-Final OA Pfizer Inc.
17766704 CORTICAL NEURAL PROGENITOR CELLS FROM IPSCS Final Rejection Cedars-Sinai Medical Center
18446256 METHODS OF TREATING OR PREVENTING RESPIRATORY CONDITIONS Non-Final OA Mesoblast, Inc.
18228016 METHOD FOR EXTRACTING EPIDERMAL CELLS Non-Final OA Hangzhou Singclean Medical Products Co., Ltd
18019357 AAV VECTORS ENCODING PARKIN AND USES THEREOF Non-Final OA Prevail Therapeutics, Inc.
17766083 Zinc Finger Protein Transcription Factors for Treatment of Prion Disease Non-Final OA Sangamo Therapeutics, Inc.
18258207 LYOPHILIZED MESENCHYMAL STEM CELLS Non-Final OA Habil F KHORAKIWALA
18024646 Quality Improving Agent for IPS Cells, Method of Producing IPS Cells, IPS Cells, and Composition for Producing IPS Cells Non-Final OA ID Pharma Co., Ltd.
18041142 GENE THERAPY VECTOR EXPRESSING CYP27A1 FOR THE TREATMENT OF CEREBROTENDINOUS XANTHOMATOSIS Final Rejection FUNDACION PARA LA INVESTIGACION MEDICA APLICADA
18000072 GENERATION OF PRIMORDIAL GERM CELLS AND METHODS OF USING THE SAME Non-Final OA The Board of Trustees of the Leland Stanfor Junior University
17818493 TRANSIENT EXPRESSION SYSTEM FOR RNA, FOR COSMETIC USES Non-Final OA GEG Tech
17743423 CHIMERIC ANTIGEN RECEPTOR CELL LIBRARY CARRYING GENE ELEMENT COMBINATION, PREPRATION AND SCREENING METHOD, AND USE THEREOF Final Rejection PHARCHOICE THERAPEUTICS INC
17772223 METHOD AND KIT FOR EXPANDING CIRCULATING TUMOR CELLS EX VIVO, COMPOSITE MATERIAL FILM AND PREPARATION METHOD THEREOF, DRUG TESTING METHOD, AND CRYOPRESERVATION SOLUTION Non-Final OA Cancer Free Biotech Ltd.
17633570 GENETIC MODIFICATION SITE Final Rejection ReNeuron Limited
17561389 METHOD FOR CULTIVATION OF ADHERENT CELLS IN A MULTIPARALLEL BIOREACTOR Final Rejection Alachua Government Services, Inc.
17551983 FOOD PRODUCTS COMPRISING CULTIVATED BOVINE CELLS AND METHODS THEREOF Final Rejection GOOD Meat, Inc.
16964624 SCREENING METHOD FOR ESTROGENIC AND ANTI-ESTROGENIC ACTIVITY Final Rejection BUNDESINSTITUT FÜR RISIKOBEWERTUNG

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month